THE COMBINATION OF TLR7/8 AND TLR4 ADJUVANTS IN AN INFLUENZA VACCINE PRODUCE UNIQUE ANTIGEN-SPECIFIC ADAPTIVE IMMUNITY AND PROTECT AGAINST LETHAL HETEROLOGOUS INFLUENZA CHALLENGE